Towards personalized treatment for early stage HER2-positive breast cancer-Reference-Cited by-同舟云学术

Towards personalized treatment for early stage HER2-positive breast cancer

Published:2019-12-13 Issue:4 Volume:17 Page:233-250
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Goutsouliak Kristina,Veeraraghavan Jamunarani^ORCID,Sethunath Vidyalakshmi^ORCID,De Angelis Carmine^ORCID,Osborne C. Kent,Rimawi Mothaffar F.^ORCID,Schiff Rachel^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://www.nature.com/articles/s41571-019-0299-9.pdf

Reference176 articles.

1. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).

2. Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997–4013 (2013).

3. Rimawi, M. F., Schiff, R. & Osborne, C. K. Targeting HER2 for the treatment of breast cancer. Annu. Rev. Med. 66, 111–128 (2015).

4. Gutierrez, C. & Schiff, R. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 135, 55–62 (2011).

5. Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469–6487 (2007).

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation chemotherapy treatments based on black hole algorithms: From cancer remission to chronic disease management;Computers in Biology and Medicine;2024-09

2. Development of a reliable cell-based reporter gene assay to measure the bioactivity of anti-HER2 therapeutic antibodies;Journal of Pharmaceutical and Biomedical Analysis;2024-08

3. Probabilistic Model of Patient Classification Using Bayesian Model;International Journal of Reliable and Quality E-Healthcare;2024-07-17

4. Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients;Clinical Breast Cancer;2024-07

5. Patient Preferences Influencing Treatment Decision-Making in Early-Stage Breast Cancer in Germany, Italy, and Japan;Patient Preference and Adherence;2024-07